Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 10/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745979 | 0.80 | PDE10A (0.66) | PDE10AMAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL14996674 | 0.77 | MAPK13 (0.44) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL14451608 | 0.75 | BRAF (0.50) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL3754852 | 0.74 | KMT2A (0.45) | PDE10AMAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL28720418 | 0.72 | MAPK10 (0.42) | PDE10AMAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL12856394 | 0.72 | TGFBR1 (0.54) | PDE10AMAPK14 | |
| SCHEMBL25251598 | 0.71 | RAB9A (0.40) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15478697 | 0.71 | BRAF (0.42) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL18865666 | 0.71 | HRH3 (0.43) | CYP1A2MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL25297726 | 0.71 | CSNK1D (0.44) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | PDE10A 17/4885CYP1A1 9/4885CYP1A2 8/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | PDE10A 17/4885CYP1A1 8/4885CYP1A2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.